Vanda Pharmaceuticals (VNDA) Profit After Tax Growth (3y) (2013 - 2026)
Vanda Pharmaceuticals (VNDA) Profit After Tax Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 9.53% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -27.65% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 70.25% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Vanda Pharmaceuticals | 310.98 Mn | 108.67 Mn | 48.56 Mn | -156.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -156.80% |
| Dec 31, 2025 | -182.64% |
| Sep 30, 2025 | -107.29% |
| Jun 30, 2025 | -132.51% |
| Mar 31, 2025 | -66.15% |
| Dec 31, 2024 | -39.14% |
| Sep 30, 2024 | -38.99% |
| Jun 30, 2024 | -35.14% |
| Mar 31, 2024 | -35.35% |
| Dec 31, 2023 | -31.87% |
| Sep 30, 2023 | -71.55% |
| Jun 30, 2023 | -44.13% |
| Mar 31, 2023 | 88.44% |
| Dec 31, 2022 | 17.62% |
| Sep 30, 2022 | -68.07% |
| Jun 30, 2022 | -39.33% |
| Mar 31, 2022 | -119.02% |
| Dec 31, 2021 | -11.93% |
| Sep 30, 2021 | 2.71% |
| Jun 30, 2021 | 27.93% |